Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...

Ozempic has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic ...

Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The FDA approved Ozempic to treat kidney disease in Type 2 diabetes patients after trials showed it reduces the risk of ...

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisks (NYSE:NVO) Ozempic for reducing the risk of kidney ...